Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Non-small Cell Lung Cancer Adenocarcinoma 1Microsatellite Stable Colorectal Cancer 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × grapiprant × Clear all
NCT03658772 2023-10-24

Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

Arrys Therapeutics

Phase 1 Completed
54 enrolled
Gastrointestinal

Microsatellite Stable Colorectal Cancer

NCT03696212 2021-02-21

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Arrys Therapeutics

Phase 1/2 Terminated
18 enrolled
Thoracic

Non-small Cell Lung Cancer Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡